Arrivent Biopharma Inc (AVBP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2026 | 03-2026 | 12-2025 | 09-2025 | 06-2025 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -93,213 | -43,320 | -166,308 | -130,764 | -95,786 |
| Depreciation Amortization | -1,074 | -559 | -3,026 | N/A | N/A |
| Accounts payable and accrued liabilities | -3,704 | 2,807 | 2,141 | 2,149 | 280 |
| Other Working Capital | 664 | -3,498 | -3,774 | -8,464 | -3,928 |
| Other Operating Activity | 15,854 | 2,678 | 10,379 | 7,149 | 5,302 |
| Operating Cash Flow | $-81,473 | $-41,892 | $-160,588 | $-129,930 | $-94,132 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 49,654 | 3,582 | -71,228 | -29 | 50,731 |
| Investing Cash Flow | $49,654 | $3,582 | $-71,228 | $-29 | $50,731 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 140,961 | 54,873 | 203,133 | 168,391 | 82,226 |
| Other Financing Activity | 0 | 0 | -70 | -53 | -353 |
| Financing Cash Flow | $140,961 | $54,873 | $203,063 | $168,338 | $81,873 |
| Beginning Cash Position | 45,540 | 45,540 | 74,293 | 74,293 | 74,293 |
| End Cash Position | 154,682 | 62,103 | 45,540 | 112,672 | 112,765 |
| Net Cash Flow | $109,142 | $16,563 | $-28,753 | $38,379 | $38,472 |
| Free Cash Flow | |||||
| Operating Cash Flow | -81,473 | -41,892 | -160,588 | -129,930 | -94,132 |
| Free Cash Flow | -81,473 | -41,892 | -160,588 | -129,930 | -94,132 |